EDG6 agonists(Sphingosine 1-phosphate receptor Edg-6 agonists), S1PR1 agonists(Sphingosine 1-phosphate receptor Edg-1 agonists), S1PR5 agonists(Sphingosine 1-phosphate receptor Edg-8 agonists)

Therapeutic Areas

Immune System DiseasesDigestive System DisordersEndocrinology and Metabolic Disease+ [2]

Active Indication

Ulcerative colitis, active moderateUlcerative colitis, active severeColitis, Ulcerative+ [4]

Inactive Indication

Alopecia AreataDiarrheaEczema+ [6]

Originator Organization

Arena Pharmaceuticals, Inc.

Active Organization

Penn Pharmaceutical Services Ltd.Pfizer Europe MA EEIG

Pfizer Inc.

+ [5]

Inactive Organization

Arena Pharmaceuticals, Inc.

License Organization

Arena Pharmaceuticals, Inc.

Yunding Xinyao Pharmaceutical Technology Co., Ltd.

Pfizer Inc.

Drug Highest PhaseApproved

First Approval Date

United States (12 Oct 2023),

Colitis, Ulcerative

Regulation-

Structure/Sequence

Molecular FormulaC32H40F3N5O5

InChIKeyGVPVVOSNDUAUKM-BPGOJFKZSA-N

CAS Registry1206123-97-8

Clinical Trials associated with Etrasimod Arginine

NCT07486921

/ RecruitingPhase 2IIT

Etrasimod as Primary and Secondary Prevention of Pouchitis (ESPIRIT)

The researchers propose conducting a multi-center, randomized, placebo-controlled study to investigate the potential role of etrasimod for the primary and secondary prevention of pouchitis among high-risk patients submitted to total proctocolectomy (TPC) with ileal-pouch anal anastomosis (IPAA) for medically refractory disease. The trial will be conducted in compliance with this protocol, Good Clinical Practice guidelines, and Institutional Review Board requirements.

Start Date12 Jun 2026

Sponsor / Collaborator

Icahn School of Medicine at Mount Sinai

[+1]

NCT07470879

/ RecruitingPhase 2

A PHASE 2 OPEN-LABEL, SINGLE ARM STUDY TO EVALUATE THE EFFICACY, PHARMACOKINETICS, AND SAFETY OF ETRASIMOD IN PEDIATRIC PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

The purpose of this study is to determine the safety, efficacy, and pharmacokinetics (PK) of etrasimod for the treatment of moderately to severely active ulcerative colitis in pediatrics participants (≥ 2 years up to < 12 years of age). Participants who will complete the total 52-week treatment period will have the opportunity to continue in a Long-Term Extension (LTE) Period of up to 4 years (5 years after study enrollment).

Start Date30 May 2026

Sponsor / Collaborator

Pfizer Inc.

NCT07459686

/ RecruitingNot Applicable

Velsipity® Tablets 2 mg Special Investigation (Investigation on Long-Term Use in Patients With Ulcerative Colitis)

A study to assess the safety and effectiveness of Velsipity Tablets 2 mg during long-term treatment (up to a maximum of 52 weeks) in patients with ulcerative colitis under actual medical practice.

Start Date27 Apr 2026

Sponsor / Collaborator

Pfizer Inc.

100 Clinical Results associated with Etrasimod Arginine

100 Translational Medicine associated with Etrasimod Arginine

100 Patents (Medical) associated with Etrasimod Arginine

136

Literatures (Medical) associated with Etrasimod Arginine

01 Jun 2026·BIOMEDICINE & PHARMACOTHERAPY

Expanding the therapeutic horizon in inflammatory bowel disease: The rise of non-cytokine compounds

Review

Author: Bernardo, David ; Gisbert, Javier P ; De Prado, Ángel ; Barrio, Jesús ; García-Alonso, F Javier ; Arribas-Rodríguez, Elisa

While cytokine-targeted therapies have significantly transformed the treatment landscape of inflammatory bowel disease (IBD), a substantial proportion of patients remain refractory or lose responsiveness over time. Moreover, cytokine blockade alone may be insufficient to control the highly complex and heterogeneous immune dysregulation that characterizes intestinal inflammation. This has prompted the development of alternative biologic and small-molecule therapies targeting non-cytokine pathways implicated in intestinal inflammation, acting at distinct regulatory levels including immune cell trafficking, intracellular signalling, and lymphocyte recirculation. Here, we review emerging and approved non-cytokine-targeted therapies in IBD, focusing on three major mechanistic categories: anti-integrin agents (vedolizumab, natalizumab, etrolizumab) that selectively block leukocyte trafficking to the intestinal mucosa; Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway inhibitors (tofacitinib, upadacitinib, filgotinib) that interrupt multiple cytokine-mediated intracellular signalling cascades; and sphingosine-1-phosphate (S1P) receptor modulators (ozanimod, etrasimod) that sequester lymphocytes within lymphoid organs by functionally antagonizing S1P1 receptors. For each therapeutic class, we summarize the mechanistic rationale, clinical efficacy, safety profiles, and positioning within current treatment algorithms. Non-cytokine-based therapies represent a critical advance in the personalized management of IBD. By targeting complementary immunological mechanisms beyond cytokine inhibition, they offer new therapeutic options for patients with treatment-refractory disease and expand the arsenal for combination strategies. Furthermore, they highlight the need for precision medicine approaches guided by immune phenotyping, pharmacokinetic monitoring, and biomarker development to optimize therapeutic selection and improve long-term outcomes.

01 Jun 2026·INFLAMMATORY BOWEL DISEASES

Rapid symptomatic improvement with etrasimod in ulcerative colitis: a post-hoc analysis of the ELEVATE UC program

Article

Author: Hur, Peter ; Goetsch, Martina ; Chaparro, María ; Irving, Peter M ; Woolcott, John C ; Wang, Wenjin ; Torres, Joana ; Sidhu, Sarah ; Panaccione, Remo ; Dubinsky, Marla C

Abstract:

Introduction:

Rapid symptom relief is an important consideration for patients with ulcerative colitis (UC) experiencing a flare. Etrasimod is an oral, once-daily, selective sphingosine 1-phosphate1,4,5 receptor modulator for the treatment of moderately to severely active UC. We evaluated patient-reported symptomatic improvement from patients in the ELEVATE UC program.

Methods:

This study was a post-hoc analysis of pooled daily e-diary data from patients with moderately to severely active UC receiving etrasimod or placebo in the phase III ELEVATE UC 52 and ELEVATE UC 12 trials. During the 12-week induction periods, patients self-reported stool frequency and rectal bleeding on days 1-28. Daily symptomatic response and symptomatic remission were calculated (partial modified Mayo Score).

Results:

Overall, 787 patients (527 receiving etrasimod, 260 placebo) were included in the analysis. Etrasimod-treated patients had statistically significantly higher rates of symptomatic response and symptomatic remission during the first 28 days of therapy, with adjusted differences (95% CIs) reaching statistical significance from day 2 (5.6% [0.8-10.3], P = .022) to day 11 (4.7% [0.4-9.0], P = .034), respectively. In patients naïve to biologic/Janus kinase inhibitor therapy, symptomatic response was statistically significantly improved with etrasimod vs placebo from day 3 (8.9% [2.3-15.5], P = .008). Symptomatic improvement rates were similar with and without concomitant corticosteroid use.

Conclusions:

In this post-hoc analysis, improvements in UC symptoms occurred in patients receiving etrasimod vs placebo from as early as day 2. These findings indicate a rapid onset of symptomatic effect with etrasimod treatment for moderately to severely active UC.

ClinicalTrials.gov numbers:

NCT03945188, NCT03996369.

08 May 2026·Journal of Crohns & Colitis

Time to rethink washout periods in inflammatory bowel disease clinical trials: an international Delphi consensus

Article

Author: Dulai, Parambir ; Jairath, Vipul ; Turner, Dan ; Danese, Silvio ; Long, Millie ; Dotan, Iris ; Sands, Bruce E ; Magro, Fernando ; Hart, Ailsa ; Armuzzi, Alessandro ; Ma, Christopher ; Reinisch, Walter ; Verstockt, Bram ; Dignass, Axel ; Peyrin-Biroulet, Laurent ; Wils, Pauline ; Rubin, David T ; Gearry, Richard ; Vieujean, Sophie ; Kobayashi, Taku

Abstract:

Background & Aims:

Prolonged washout periods between advanced therapies and investigational drugs are commonly required in inflammatory bowel disease (IBD) randomized controlled trials (RCTs). These requirements restrict patient enrollment and diverge from real-world clinical practice. This study aimed to establish an international expert consensus on washout durations for advanced therapies and conventional immunosuppressants (IS) in IBD clinical trials and to propose methodological recommendations for future study designs.

Methods:

An international panel of 12 IBD clinical trial experts participated in a Delphi consensus process. Agreement of ≥75% among participants was predefined as consensus.

Results:

A total of 12 statements were approved. Consensus was reached to eliminate washout periods for conventional IS (thiopurines, tacrolimus, methotrexate, and mycophenolate mofetil). For golimumab and ozanimod, experts agreed on a 2-week washout period. For other biologics (infliximab, adalimumab, vedolizumab, ustekinumab, and anti–IL-23 agents), most participants favored a 2–4-week washout duration and for JAK inhibitors and etrasimod, participants supported a short 2-week washout, though without reaching formal consensus. Experts recommended incorporating washout-based stratification (<4 vs ≥4 weeks) at randomization into future trial designs to evaluate its impact on safety, pharmacokinetics, and efficacy outcomes.

Conclusions:

This international Delphi consensus highlights the need to adapt current washout practices in IBD RCTs to real-world practice. Experts supported shorter and standardized washout durations—preferably less than 4 weeks—to better align with clinical practice, while maintaining patient safety. Acceptance of these recommendations by regulators could harmonize washout duration criteria, enhance recruitment efficiency, and accelerate patient access to innovative therapies without compromising safety.

134

News (Medical) associated with Etrasimod Arginine

25 May 2026

·www.everestmedicines.com

Everest Medicines Announces Approval for VELSIPITY® by South Korea’s Ministry of Food and Drug Safety for the Treatment of Moderately to Severely Active Ulcerative Colitis

SHANGHAI, China - May 25, 2026 - Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the Ministry of Food and Drug Safety (MFDS) in South Korea, has officially approved the New Drug Application (NDA) for Etrasimod (VELSIPITY®) for the treatment of adult with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy (corticosteroids or immunosuppressants) or a biologic agent. Following prior approvals in Macao SAR, Singapore, Hong Kong SAR, and Chinese mainland, this achievement marks another milestone in expanding access to this innovative therapy for patients across the region. Ulcerative colitis is a chronic, relapsing, non-specific inflammatory bowel disease characterized by symptoms such as mucus and blood in the stool, abdominal pain, diarrhea, and rectal tenesmus, which can significantly impact patients' daily lives and long-term health. There remains a critical need for therapies that offer sustained and comprehensive disease control. VELSIPITY® is a next-generation, highly selective S1P receptor modulator with best-in-disease potential and strong first-line treatment recommendations in leading international guidelines. Early achievement of mucosal healing is recognized as a key treatment goal, as it can significantly reduce rates of disease relapse, hospitalization, surgery, and the risk of progression to colorectal cancer. VELSIPITY® addresses this need by targeting intestinal inflammation at its source and promoting mucosal healing, while offering a favorable profile of efficacy and safety, along with the convenience of an oral, once-daily regimen, supporting sustained disease management and improving patients' quality of life. It has been strongly recommended as a first-line treatment for moderately to severely active UC in both the American Gastroenterological Association (AGA) Clinical Practice Guideline and the American College of Gastroenterology (ACG) Clinical Guideline Update, reflecting strong recognition of its efficacy and safety by leading international academic societies. "We are pleased that the NDA for VELSIPITY® has been officially approved in South Korea. This represents an important milestone in our expansion in the autoimmune disease field and underscores our commitment to making this innovative therapy widely available in the region,” said Mr. Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “The burden of ulcerative colitis in the region continues to rise. In South Korea, the number of patients has grown at a compound annual growth rate of approximately 6% over the past five years. In 2024, the total patient population was around 64,000, and this is projected to increase to 90,000 by 2030. As a next-generation, highly selective S1P receptor modulator, VELSIPITY® combines efficacy, safety, and convenience, making it a promising treatment option for patients with moderately to severely active UC in South Korea. It offers both greater convenience and long-term disease management. Everest Medicines will continue to bring innovative therapies to patients across Asia in the future.” The approval of VELSIPITY® in South Korea was supported by results from the global ELEVATE UC Phase 3 program (including the ELEVATE UC 52 and ELEVATE UC 12 studies) and the Asian multicenter Phase 3 registrational ENLIGHT UC study (ES101002). ELEVATE UC 52 and ELEVATE UC 12 are randomized, double-blind, placebo-controlled clinical studies in the global ELEVATE UC Phase 3 program. Both studies achieved all primary and key secondary efficacy endpoints, demonstrated statistically significant improvements in clinical remission and mucosal healing, along with a favorable safety profile. The ENLIGHT UC study (ES101002) is a randomized, double-blind, placebo-controlled clinical study of the largest Phase 3 trial of moderately to severely active UC in Asia (including Chinese mainland, Chinese Taiwan, and South Korea) completed to date, with 340 eligible subjects randomized to treatment with Etrasimod or placebo. Results from the ENLIGHT UC study demonstrated that the clinical remission rate at week 40 of the maintenance period reached 48.1%, and the deep mucosal healing rate reached 51.9%, with an endoscopic mucosal normalization rate of 45.5%1. As the first Phase 3 registrational study in Asian patients with moderately to severely active UC, the study confirms the efficacy and safety of VELSIPITY® in this population, with results published in The Lancet Gastroenterology & Hepatology1. Its approval represents an important milestone and validation, providing patients with a novel treatment option and advancing UC management. Results from the ELEVATE UC open-label extension demonstrate continuous treatment with VELSIPITY® for up to 3 years resulted in 86.8% of patients achieving a clinical response among the observed cases, with both clinical remission and mucosal healing rates maintained at approximately 60%2. Safety data extending up to five years from the global clinical program further confirm that VELSIPITY® is well tolerated and maintains a favorable and stable safety profile3. Global and Asia-Pacific clinical evidence has demonstrated that VELSIPITY® is effective and well-tolerated across patient populations with different disease stages and treatment backgrounds, providing a solid foundation for its standardized use in real-world clinical practice. VELSIPITY® has been approved in several territories licensed to Everest Medicines, including Chinese mainland, Hong Kong SAR, Macao SAR, and Singapore. In February 2026, the National Medical Products Administration (NMPA) of China granted approval for VELSIPITY®, and the therapy was prescribed within one month. This highlights Everest’s capability to rapidly bring innovative therapies to patients. To ensure long-term supply and support commercialization, Everest launched a localized production project for VELSIPITY® at its Jiashan manufacturing site in March 2025, strengthening its supply capabilities for Greater China and other Asian markets. References: 1. 1.K. Wu, et al. Lancet Gastroenterol Hepatol. 2025 Sep 30:S2468-1253(25)00198-0. 2. B E Sands, et al. ECCO 2026. Abstract ID: jjaf231.774. 3. D.T. Rubin, et al. ECCO 2026. Abstract ID: jjaf231.1256. About VELSIPITY® (Etrasimod) VELSIPITY® is a once-daily, oral, sphingosine 1-phosphate (S1P) receptor modulator that selectively binds to S1P receptor subtypes 1, 4, and 5. Regulatory approvals have been granted in US, EU, Canada, Japan, Australia, Singapore, UK, Switzerland, Israel, Turkey, India, Hong Kong SAR, Macao SAR and Chinese Mainland for VELSIPITY® in ulcerative colitis, as well as in additional countries. About Everest Medicines Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies. The Company’s therapeutic areas of focus include autoimmune, ophthalmology, critical care, and CKM (cardiovascular, kidney, and metabolic) diseases. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company's website: www.everestmedicines.com. Forward-Looking Statements This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.

Phase 3Drug ApprovalClinical Result

21 May 2026

·www.einpresswire.com

UChicago Medicine builds on years of experience with new oral IBD treatment

A growing body of real-world evidence continues to show that upadacitinib, the first oral medication approved by the FDA to treat Crohn’s disease and the second drug in its class for ulcerative colitis, is not only safe but fast acting and effective. This makes it a novel and significant new option for patients with moderate to severe Crohn’s disease and ulcerative colitis. In a new study evaluating the long-term safety of upadacitinib (marketed as Rinvoq) during six clinical trials, researchers found that rates of serious complications like blood clots in the legs, heart attacks, and cancer remained low throughout treatment. “Ahead of its approval, I thought that this drug would be a game changer because it brings a new mechanism as well as a new, non-biological delivery system to patients with Crohn's disease and ulcerative colitis,” said David T. Rubin, MD , Director of the Inflammatory Bowel Disease Center at the University of Chicago Medicine. “These new data about its safety are reassuring, so that we can use it properly in more patients.” Rubin is the senior author of the new study, which published in Clinical Gastroenterology and Hepatology . A new, more effective way to do the job Other FDA-approved drugs for IBD are so-called “biologic” treatments that use proteins like monoclonal antibodies to target other immune proteins that drive inflammation in many diseases. They are administered by injections or regular infusions, which can make them costly and inconvenient for many patients. These biologic drugs also face another challenge in treating Crohn’s and ulcerative colitis: when the lining of the intestine is inflamed during a flare-up of the disease, it becomes more porous, letting these proteins leak through the bowel wall and therefore limiting their efficacy as an anti-inflammatory therapy. Rinvoq is one of a new generation of drugs that are small molecules — small enough to be delivered effectively in a once-daily pill, allowing the treatment to be absorbed directly through the lining of the small intestine and avoid the leakage issue associated with biologic therapies. Rinvoq is a Janus kinase (JAK) inhibitor, meaning it works by blocking an enzyme on the walls of cells. In this case, Rinvoq blocks one of four kinases (JAK-1) that shuts down three different inflammatory pathways, making it a potent and effective way to control inflammation. “This is a novel treatment strategy that is not just a different mechanism of action, but, because of its delivery system, potentially a much more effective way to get the drug into people to do the job,” Rubin said. In other studies, most patients began to improve after just three days of treatment; 21% reported feeling better after just one dose. Real-world experience The new paper is an analysis of clinical trials conducted by AbbVie, the manufacturer of Rinvoq. The drug was first approved by the FDA to treat rheumatoid arthritis in 2019, and later for ulcerative colitis (2022) and Crohn’s disease (2023). Rubin and his colleagues at the IBD Center have spent years evaluating the real-world experience of patients taking Rinvoq and other new therapies for IBD. They were the first researchers in the world to publish about their experience treating Crohn’s and ulcerative colitis with Rinvoq in the real world in 2023, and this year, they were the first to publish data showing that patients responded well when higher doses of Rinvoq were reintroduced after they stopped responding to lower maintenance doses. “We have such a large set of patients and now we're on the cutting edge of using these therapies. We're working at the regulatory level, we're working with clinical trials, and we're working with patients in the clinic in the real world,” Rubin said. “We are proud to have one of the fastest and most prolific real world data centers in IBD at UChicago, thanks to our large, amazing patient population and our collaborative work across disciplines. The real-world experience is a critical part of understanding how to treat people with these immune conditions more effectively and safely.” Disclosure: David T. Rubin is a paid consultant of AbbVie, Bristol Myers Squibb, Johnson & Johnson, and Pfizer, the makers of therapies for IBD including Rinvoq, Xeljanz, and Velsipity. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

09 Apr 2026

·www.pharmaceutical-technology.com

EverSea Medicines to acquire Hasten Biopharmaceuticals

The acquisition includes MAH rights, trademarks, and commercial rights for 14 chronic disease products in Asia Pacific. Credit: MiniStocker / Shutterstock.com. Everest Medicines’ wholly owned subsidiary EverSea Medicines (Singapore) has signed a share purchase agreement to conditionally acquire Hasten Biopharmaceuticals, a subsidiary of Hasten Biopharmaceuticals (Asia). The acquisition aims to enhance Everest Medicines’ presence and commercial capabilities across key regional markets. Under the deal, Everest Medicines will pay a total consideration of $250m in three instalments: $150m at closing, and two further $50m payments due in the first quarters of 2028 and 2029, subject to agreed conditions precedent. Hasten Biopharmaceuticals (Asia) will also pay a refundable deposit of 200m yuan ($29.2m) to Everest Medicines within ten days after closing. Upon closing, Everest Medicines will consolidate the financial results of Hasten Biopharmaceuticals. The acquisition includes trademark and broad commercial rights and marketing authorisation holder (MAH) rights for 14 branded chronic disease products that are owned by Hasten Biopharmaceuticals in various Asia Pacific jurisdictions. In December 2025, Hasten Biopharmaceuticals posted normalised revenue of $82.23m and EBITDA of $27.27m. The company commercialises prescription pharmaceuticals with a focus on chronic and acute/critical care, targeting the metabolic and cardiovascular segments. Everest Medicines has a pipeline that is focused on chronic disease therapeutic areas such as cardiovascular, kidney, and metabolic illnesses. Its products, including Nefecon, Velsipity, and Xerava, are advancing through new drug application and reimbursement processes in Asian markets. The company expects the acquisition to further expedite regional product commercialisation and overseas revenue generation. It will also expand Everest Medicines’ existing commercialisation capabilities from China to the Asia Pacific, supporting market entry and the development of infrastructure needed for international growth. In February 2026, Everest Medicines signed an exclusive licence agreement with Micot to commercialise MT1013 in China and the Asia Pacific (excluding Japan).

License out/inAcquisition

100 Deals associated with Etrasimod Arginine

External Link

KEGG	Wiki	ATC	Drug Bank
D10930	-	-	DB14766

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Ulcerative colitis, active moderate	European Union	Pfizer Europe MA EEIG	16 Feb 2024
Ulcerative colitis, active moderate	Iceland	Pfizer Europe MA EEIG	16 Feb 2024
Ulcerative colitis, active moderate	Liechtenstein	Pfizer Europe MA EEIG	16 Feb 2024
Ulcerative colitis, active moderate	Norway	Pfizer Europe MA EEIG	16 Feb 2024
Ulcerative colitis, active severe	European Union	Pfizer Europe MA EEIG	16 Feb 2024
Ulcerative colitis, active severe	Iceland	Pfizer Europe MA EEIG	16 Feb 2024
Ulcerative colitis, active severe	Liechtenstein	Pfizer Europe MA EEIG	16 Feb 2024
Ulcerative colitis, active severe	Norway	Pfizer Europe MA EEIG	16 Feb 2024
Colitis, Ulcerative	United States	Pfizer Inc.	12 Oct 2023

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Eczema	Phase 3	United States	Pfizer Inc.	18 Jan 2023
Eczema	Phase 3	Canada	Pfizer Inc.	18 Jan 2023
Eczema	Phase 3	Czechia	Pfizer Inc.	18 Jan 2023
Eczema	Phase 3	Poland	Pfizer Inc.	18 Jan 2023
Moderate Atopic Dermatitis	Phase 3	United States	Pfizer Inc.	18 Jan 2023
Moderate Atopic Dermatitis	Phase 3	Canada	Pfizer Inc.	18 Jan 2023
Moderate Atopic Dermatitis	Phase 3	Czechia	Pfizer Inc.	18 Jan 2023
Moderate Atopic Dermatitis	Phase 3	Poland	Pfizer Inc.	18 Jan 2023
Severe Atopic Dermatitis	Phase 3	United States	Pfizer Inc.	18 Jan 2023
Severe Atopic Dermatitis	Phase 3	Canada	Pfizer Inc.	18 Jan 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05061446 (Pubmed \| Intest Res)	Phase 2	Colitis, Ulcerative	-	Etrasimod 1 mg QD	zuqizsojzs(lrypnizxfv) = ziqkiiligz ydzkgjqhks (zvcifhiylt ) View more	Positive	30 Apr 2026
				Etrasimod 2 mg QD	zuqizsojzs(lrypnizxfv) = rxvdzujcim ydzkgjqhks (zvcifhiylt ) View more
ELEVATE UC OLE (ECCO2026)	Phase 2/3	Colitis, Ulcerative	390	Etrasimod (biologic/JAKi naïve)	wtlhsdykfg(nmnlzaefmq) = lvpppqvzek mrcknsqbag (edzdgiqfmx ) View more	Positive	18 Feb 2026
ECCO2026	Not Applicable	Colitis, Ulcerative	20	Etrasimod 2mg	bzkczpmaaq(wgdbhfeqaz) = fumtdnlfui dcrfuvfdyn (uvbgcxvzau ) View more	Positive	18 Feb 2026
NCT03950232 (ELEVATE UC, ECCO2026)	Phase 3	Colitis, Ulcerative	214	Etrasimod 2 mg QD	lzosanrfyn(xfrywjldir) = vnuuzfcqme pbkrkzyrof (rnwzjftxim ) View more	Positive	18 Feb 2026
NCT04176588 (ENLIGHT UC, ECCO2026)	Phase 3	Ulcerative colitis, active severe	340	Etrasimod 2 mg	nquzvbymdb(gfxfaruyxh) = lwzqimqfig fmxkplwvmz (xwadpyzidb ) View more	Positive	18 Feb 2026
				Placebo	nquzvbymdb(gfxfaruyxh) = srdisdoqqa fmxkplwvmz (xwadpyzidb ) View more
ECCO2026	Not Applicable	Colitis, Ulcerative	39	Etrasimod 2 mg	ixlgsdsozl(iwdyhfqvht) = dlncjprexb jzheckuiki (lmnlkwdhxo ) View more	Positive	18 Feb 2026
NCT03996369 \| NCT03945188 (ELEVATE UC Clinical Program, Pubmed \| Am J Gastroenterol)	Phase 3	Colitis, Ulcerative	-	Etrasimod 2 mg QD	agmqodcyfm(utshqqunpv) = oonanruaxj glzcanswii (aqzzuvjhnh )	Positive	01 Nov 2025
				Placebo	agmqodcyfm(utshqqunpv) = pyzgdvpcgz glzcanswii (aqzzuvjhnh )
NCT04176588 (ENLIGHT UC, Pubmed) Manual	Phase 3	Ulcerative colitis, active severe	340	Etrasimod 2 mg	zyaweyqsbw(awmjnmyezd) = edmtyktdas kcyfcvxmrh (opjdrwfwtb ) View more	Positive	30 Sep 2025
				Placebo	zyaweyqsbw(awmjnmyezd) = fustrwkenp kcyfcvxmrh (opjdrwfwtb ) View more
NEWS Manual	Phase 3	Colitis, Ulcerative First line	1,196	etrasimod	nwwjxpeghx(bkhsyxhnug) = gtnxcselvd esngxomodk (xauhxhubti ) View more	Positive	17 Jul 2025
				Placebo	nwwjxpeghx(bkhsyxhnug) = eliqvtwrpz esngxomodk (xauhxhubti ) View more
NCT04176588 (ENLIGHT, NEWS) Manual	Phase 3	Colitis, Ulcerative	340	伊曲莫德	ywdrrlrjii(uhtafauwmu) = faxndvciey afpzpnjqxu (cljluagtyo ) View more	Positive	17 Jul 2025

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis